Table 1.
Characteristics of patients included in the study (n = 88)
| Parameters | Value |
|---|---|
| Age, years, M ± σ | 47 ± 13 |
| Sex, n (%) | |
| – female | 73 (83) |
| – male | 15 (17) |
| Disease subset, n (%) | |
| – limited | 30 (34) |
| – diffuse | 50 (57) |
| – overlap | 8 (9) |
| Interstitial lung disease, n (%) | 70 (80) |
| Disease duration, years, M ± σ | 5.9 ± 4.8 |
| Follow up, month, M ± σ | 26.3 ± 10.7 |
| Prednisolone mg/day, M ± σ | 11.7 ± 4.4 |
| Immunosupressants at baseline, n (%) | 37 (42) |
| Cumulative mean dose of RTX (gr), M ± σ | 2.9 ± 1.1 |
| ANA HEp-2, n (%) | 88 (100) |
| A-Topo-1 positivity, n (%) | 63 (75) |
| ACA positivity, n (%) | 3 (3.4) |
RTX, rituximab; ANA, antinuclear antibody; A-Topo-1, anti-topoisomerase 1 antibody; ACA, anti-centromere antibody.